News

BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage. In this study, 116 women with metastatic TNBC, defined by tumors

Interim results from the ongoing Phase II dose-escalation study were presented at the 2009 Annual Meeting of American Society of Clinical Oncology. Cynthia Sullivan, President and CEO, said:

During the clinical trial, 151 blood samples were analyzed from 42 patients enrolled in the randomized Phase II study of figitumumab in combination with carboplatin and paclitaxel in

For c-Met study, among 19 NSCLC patients who had an EML4-ALK mutation treated with PF-02341066, 10 have had a partial response, with three unconfirmed; the duration of response

The median overall survival in patients with advanced metastatic prostate cancer, who were treated with OGX-011 plus docetaxel in a randomized phase II trial, was 23.8 months compared

Results from the study showed that after initial treatment with Avastin and chemotherapy, combined maintenance treatment with Avastin and Tarceva extends the time patients live without their disease

In this single arm phase II study, 22 patients with newly diagnosed and optimally resected EGFRvIII-positive GBM received CDX-110 in combination with maintenance temozolomide after having completed chemoradiation

Catalyst intends to investigate the reasons for the disparity between the trial results and previously published clinical and non-clinical results evaluating vigabatrin as a treatment for cocaine addiction.

According to IMS Health, Mylan has currently 117 ANDAs pending FDA approval, representing $82.1 billion in annual brand sales. Moreover, IMS also said that 35 of these pending